Real-world Study on Adjuvant Octreotide Therapy in pNETs

• Status: Completed
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk G2 pNET patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• pNETs lesions pathologically classified as WHO grade 2

• Complete surgical resection (R0 or R1 was achieved)

• Adjuvant treatment was performed within 12 weeks after surgery

Exclusion Criteria:

• Stage IV

• Other oncological history

• Previous antineoplastic systemic therapy

• Lack of information/details on recurrence or death.